Slingshot members are tracking this corporate initiative:
Juno Therapeutics Signs Licensing Agreement with Lilly to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Dec 06, 2017 Projected Implementation: Q1, 2018 Relevance Tracked Until: Q3, 2018
Don’t see a project related to the strategic initiative you care about?
Related Keywords T-cell Therapy, Multiple Myeloma